drugset / Trial / NCT00548964

Continuation Ketamine in Major Depression

NCT00548964

Phase 1 Completed 36 enrolled James Murrough
Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic (a drug used to produce loss of consciousness before and during surgery). Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study.

Timeline

Start
2007-10
Primary completion
2013-07
Completion
2013-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous
Subject Lithium Unknown 600 mg
Subject Lithium Unknown 900 mg